HRP20240525T1 - Pripravak na bazi lipida za oralnu primjenu antagonista bradikininskog b2-receptora - Google Patents
Pripravak na bazi lipida za oralnu primjenu antagonista bradikininskog b2-receptora Download PDFInfo
- Publication number
- HRP20240525T1 HRP20240525T1 HRP20240525TT HRP20240525T HRP20240525T1 HR P20240525 T1 HRP20240525 T1 HR P20240525T1 HR P20240525T T HRP20240525T T HR P20240525TT HR P20240525 T HRP20240525 T HR P20240525T HR P20240525 T1 HRP20240525 T1 HR P20240525T1
- Authority
- HR
- Croatia
- Prior art keywords
- weight
- propylene glycol
- liquid pharmaceutical
- pharmaceutical preparation
- liquid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21189990 | 2021-08-05 | ||
| EP22760986.4A EP4203919B1 (en) | 2021-08-05 | 2022-08-05 | Lipid-based composition for oral administration of bradykinin b2-receptor antagonists |
| PCT/EP2022/072049 WO2023012322A1 (en) | 2021-08-05 | 2022-08-05 | Lipid-based composition for oral administration of bradykinin b2-receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240525T1 true HRP20240525T1 (hr) | 2024-07-05 |
Family
ID=77226756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240525TT HRP20240525T1 (hr) | 2021-08-05 | 2022-08-05 | Pripravak na bazi lipida za oralnu primjenu antagonista bradikininskog b2-receptora |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20240350418A1 (https=) |
| EP (1) | EP4203919B1 (https=) |
| JP (1) | JP2024528195A (https=) |
| KR (1) | KR20240039185A (https=) |
| CN (1) | CN118076342B (https=) |
| AU (1) | AU2022323749A1 (https=) |
| BR (1) | BR112024002215A2 (https=) |
| CA (1) | CA3227476A1 (https=) |
| CO (1) | CO2024001171A2 (https=) |
| DK (1) | DK4203919T3 (https=) |
| ES (1) | ES2978563T3 (https=) |
| FI (1) | FI4203919T3 (https=) |
| HR (1) | HRP20240525T1 (https=) |
| HU (1) | HUE066306T2 (https=) |
| IL (1) | IL310321A (https=) |
| LT (1) | LT4203919T (https=) |
| MA (1) | MA61123B1 (https=) |
| MX (1) | MX2024001711A (https=) |
| PL (1) | PL4203919T3 (https=) |
| PT (1) | PT4203919T (https=) |
| RS (1) | RS65427B1 (https=) |
| SI (1) | SI4203919T1 (https=) |
| SM (1) | SMT202400157T1 (https=) |
| WO (1) | WO2023012322A1 (https=) |
| ZA (1) | ZA202401504B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117224522B (zh) * | 2023-11-15 | 2024-02-23 | 北京协和药厂有限公司 | 药物组合物及其制备方法、药物制剂 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2218554T3 (es) | 1994-10-27 | 2004-11-16 | Fujisawa Pharmaceutical Co., Ltd. | Piridopirimidonas, quinolinas y n-heterociclos condensados que son antagonistas de bradiquinina. |
| FR2737892B1 (fr) | 1995-08-17 | 1997-10-24 | Fournier Ind & Sante | Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique |
| GB9602029D0 (en) | 1996-02-01 | 1996-04-03 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
| DE19609827A1 (de) | 1996-03-13 | 1997-09-18 | Hoechst Ag | Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten |
| DE19610784A1 (de) | 1996-03-19 | 1997-09-25 | Hoechst Ag | Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung |
| AUPN952696A0 (en) | 1996-04-29 | 1996-05-23 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| DE19712960A1 (de) | 1997-03-27 | 1998-10-01 | Hoechst Ag | Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten |
| JP2002517461A (ja) | 1998-06-08 | 2002-06-18 | アドバンスド メディスン インコーポレーテッド | ブラジキニンアンタゴニスト |
| CA2364178C (en) | 2000-12-05 | 2006-01-10 | Yasuhiro Katsu | N-benzenesulfonyl l-proline compounds as bradykinin antagonists |
| WO2008055146A2 (en) * | 2006-10-31 | 2008-05-08 | Wyeth | Formulations of phospholipase enzyme inhibitors |
| TWI407960B (zh) | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽ｂ２受體調節劑 |
| AR073304A1 (es) | 2008-09-22 | 2010-10-28 | Jerini Ag | Moduladores del receptor de bradiquinina b2 de molecula pequena |
| WO2014159637A1 (en) | 2013-03-14 | 2014-10-02 | Shire Human Genetic Therapies, Inc. | Methods of treating b2-bradykinin receptor mediated angioedema |
| AR113839A1 (es) | 2017-11-24 | 2020-06-17 | Pharvaris B V | Antagonistas del receptor b2 de bradiquinina |
-
2022
- 2022-08-05 MA MA61123A patent/MA61123B1/fr unknown
- 2022-08-05 IL IL310321A patent/IL310321A/en unknown
- 2022-08-05 KR KR1020247007280A patent/KR20240039185A/ko active Pending
- 2022-08-05 CN CN202280067108.5A patent/CN118076342B/zh active Active
- 2022-08-05 PT PT227609864T patent/PT4203919T/pt unknown
- 2022-08-05 HU HUE22760986A patent/HUE066306T2/hu unknown
- 2022-08-05 BR BR112024002215A patent/BR112024002215A2/pt unknown
- 2022-08-05 ES ES22760986T patent/ES2978563T3/es active Active
- 2022-08-05 FI FIEP22760986.4T patent/FI4203919T3/fi active
- 2022-08-05 AU AU2022323749A patent/AU2022323749A1/en active Pending
- 2022-08-05 SM SM20240157T patent/SMT202400157T1/it unknown
- 2022-08-05 SI SI202230031T patent/SI4203919T1/sl unknown
- 2022-08-05 CA CA3227476A patent/CA3227476A1/en active Pending
- 2022-08-05 RS RS20240456A patent/RS65427B1/sr unknown
- 2022-08-05 EP EP22760986.4A patent/EP4203919B1/en active Active
- 2022-08-05 PL PL22760986.4T patent/PL4203919T3/pl unknown
- 2022-08-05 LT LTEPPCT/EP2022/072049T patent/LT4203919T/lt unknown
- 2022-08-05 DK DK22760986.4T patent/DK4203919T3/da active
- 2022-08-05 MX MX2024001711A patent/MX2024001711A/es unknown
- 2022-08-05 WO PCT/EP2022/072049 patent/WO2023012322A1/en not_active Ceased
- 2022-08-05 HR HRP20240525TT patent/HRP20240525T1/hr unknown
- 2022-08-05 US US18/681,298 patent/US20240350418A1/en active Pending
- 2022-08-05 JP JP2024506610A patent/JP2024528195A/ja active Pending
-
2024
- 2024-02-05 CO CONC2024/0001171A patent/CO2024001171A2/es unknown
- 2024-02-20 ZA ZA2024/01504A patent/ZA202401504B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2978563T3 (es) | 2024-09-16 |
| PL4203919T3 (pl) | 2024-06-10 |
| FI4203919T3 (fi) | 2024-05-03 |
| KR20240039185A (ko) | 2024-03-26 |
| SI4203919T1 (sl) | 2024-08-30 |
| RS65427B1 (sr) | 2024-05-31 |
| US20240350418A1 (en) | 2024-10-24 |
| PT4203919T (pt) | 2024-04-23 |
| EP4203919A1 (en) | 2023-07-05 |
| EP4203919B1 (en) | 2024-01-31 |
| CN118076342B (zh) | 2025-08-05 |
| HUE066306T2 (hu) | 2024-07-28 |
| ZA202401504B (en) | 2025-06-25 |
| MA61123B1 (fr) | 2024-06-28 |
| CA3227476A1 (en) | 2023-02-09 |
| CO2024001171A2 (es) | 2024-05-20 |
| CN118076342A (zh) | 2024-05-24 |
| JP2024528195A (ja) | 2024-07-26 |
| AU2022323749A1 (en) | 2024-02-08 |
| DK4203919T3 (da) | 2024-04-29 |
| BR112024002215A2 (pt) | 2024-04-30 |
| SMT202400157T1 (it) | 2024-05-14 |
| IL310321A (en) | 2024-03-01 |
| WO2023012322A1 (en) | 2023-02-09 |
| MX2024001711A (es) | 2024-03-05 |
| TW202320774A (zh) | 2023-06-01 |
| LT4203919T (lt) | 2024-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2866933T3 (es) | Regímenes de dosificación de amisulprida para tratar náuseas y vómitos | |
| ES2496099T3 (es) | El uso de amisulprida para el tratamiento de náuseas y vómitos inducidos por la quimioterapia | |
| HRP20090341T1 (hr) | Mekane kapsule koje sadrže palonosetron hidroksiklorid s poboljšanom stabilnosti i bioraspoloživosti | |
| JP3743449B2 (ja) | ４，５−エポキシモルヒナン誘導体を含有する安定なソフトカプセル剤 | |
| US20040092428A1 (en) | Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof | |
| ES2640572T3 (es) | Formulaciones parenterales mejoradas de agentes farmacéuticos lipófilos y procedimientos de preparación y uso de las mismas | |
| JP2005002123A5 (https=) | ||
| BR112014028602B1 (pt) | Formulação líquida não aquosa oralmente biodisponível para administração oral | |
| RU2001129362A (ru) | Композиция, включающая ундеканоат тестостерона и касторовое масло | |
| KR950031069A (ko) | 골손실의 억제 및 혈청 콜레스테롤의 강하 방법 | |
| BRPI0008228B1 (pt) | composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes | |
| SA90100287B1 (ar) | كبسولات صيدلية تحتوي على رانيتيدين | |
| HRP20240525T1 (hr) | Pripravak na bazi lipida za oralnu primjenu antagonista bradikininskog b2-receptora | |
| PT1392318E (pt) | 15-ceto-prostaglandinas para o tratamento de obstipação induzida por fármacos | |
| JP3070930B2 (ja) | 脳血管性疾患治療剤および抗炎症剤 | |
| ITMI962423A1 (it) | Composizione farmaceutica orale ad attivita' antipiretica analgesica e infiammatoria | |
| JP2024528195A5 (https=) | ||
| BR112020012157A2 (pt) | composição farmacêutica oral de um antagonista de nk-1 | |
| US5063242A (en) | 7-((substituted)amino)-8-((substituted)carbonyl)-methylamino-1-oxaspiro[4,5]decanes as diuretics antiinflammatory, and cerebrovascular agents | |
| ES2472424T3 (es) | Composición de mitotano automicroemulsionante | |
| PT95422B (pt) | Processo para a preparacao de composicoes farmaceuticas para o tratamento de psoriase incorporando compostos de acidos alquilfosforicos | |
| Yedinak | Use of Calcium Channel Antagonists for cardiovascular disease: This CE program reviews the role of calcium channel antagonists in managing certain diseases and compares agents | |
| JP3748912B2 (ja) | オーレオバシジン類の高濃度溶液製剤 | |
| JP2017513895A (ja) | ブレクスピプラゾールとナルメフェンの組み合わせ剤及び物質関連障害を治療するためのその用途 | |
| JP2014208617A (ja) | 医薬組成物 |